Fairmount Funds Management LLC - 22 Jan 2026 SCHEDULE 13D/A Report for Apogee Therapeutics, Inc. Common Stock, $0.00001 par value (APGE)

Key filing fact

Fairmount Funds Management LLC disclosed 10% ownership in Apogee Therapeutics, Inc. Common Stock, $0.00001 par value (APGE) on 22 Jan 2026.

Key facts

Fairmount Funds Management LLC filed SCHEDULE 13D/A for Apogee Therapeutics, Inc. Common Stock, $0.00001 par value (APGE).
Disclosed ownership: 10%.
Date of event: 22 Jan 2026.

This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
You can verify ownership claims directly against the original SEC filing.

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

Reporting persons

Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name	Ownership	Shares Owned	sole voting power	shared voting power	Signature	Title	CIK
Fairmount Funds Management LLC	9.8%	5,948,385	0	5,948,385	/s/ Peter Harwin	Peter Harwin, Managing Member	0001802528
Fairmount Healthcare Fund II L.P.	9.8%	5,948,385	0	5,948,385	/s/ Peter Harwin	Peter Harwin, Managing Member	0001769651
Peter Evan Harwin	10%	6,047,027	93,374	5,953,653	/s/ Peter Harwin	Peter Harwin	0001663607
Tomas Kiselak	10%	6,047,027	93,374	5,953,653	/s/ Tomas Kiselak	Tomas Kiselak	0001830177

CIK / CUSIP context first

Broader feeds